These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

373 related items for PubMed ID: 17142512

  • 1. Safety, efficacy, and effectiveness of cold-adapted influenza vaccine-trivalent against community-acquired, culture-confirmed influenza in young children attending day care.
    Vesikari T, Fleming DM, Aristegui JF, Vertruyen A, Ashkenazi S, Rappaport R, Skinner J, Saville MK, Gruber WC, Forrest BD, CAIV-T Pediatric Day Care Clinical Trial Network.
    Pediatrics; 2006 Dec; 118(6):2298-312. PubMed ID: 17142512
    [Abstract] [Full Text] [Related]

  • 2. Influenza vaccine immunogenicity in 6- to 23-month-old children: are identical antigens necessary for priming?
    Walter EB, Neuzil KM, Zhu Y, Fairchok MP, Gagliano ME, Monto AS, Englund JA.
    Pediatrics; 2006 Sep; 118(3):e570-8. PubMed ID: 16950948
    [Abstract] [Full Text] [Related]

  • 3. Superior relative efficacy of live attenuated influenza vaccine compared with inactivated influenza vaccine in young children with recurrent respiratory tract infections.
    Ashkenazi S, Vertruyen A, Arístegui J, Esposito S, McKeith DD, Klemola T, Biolek J, Kühr J, Bujnowski T, Desgrandchamps D, Cheng SM, Skinner J, Gruber WC, Forrest BD, CAIV-T Study Group.
    Pediatr Infect Dis J; 2006 Oct; 25(10):870-9. PubMed ID: 17006279
    [Abstract] [Full Text] [Related]

  • 4. Efficacy and safety of a live attenuated, cold-adapted influenza vaccine, trivalent against culture-confirmed influenza in young children in Asia.
    Tam JS, Capeding MR, Lum LC, Chotpitayasunondh T, Jiang Z, Huang LM, Lee BW, Qian Y, Samakoses R, Lolekha S, Rajamohanan KP, Narayanan SN, Kirubakaran C, Rappaport R, Razmpour A, Gruber WC, Forrest BD, Pan-Asian CAIV-T Pediatric Efficacy Trial Network.
    Pediatr Infect Dis J; 2007 Jul; 26(7):619-28. PubMed ID: 17596805
    [Abstract] [Full Text] [Related]

  • 5. Efficacy and safety of 1 and 2 doses of live attenuated influenza vaccine in vaccine-naive children.
    Bracco Neto H, Farhat CK, Tregnaghi MW, Madhi SA, Razmpour A, Palladino G, Small MG, Gruber WC, Forrest BD, D153-P504 LAIV Study Group.
    Pediatr Infect Dis J; 2009 May; 28(5):365-71. PubMed ID: 19395948
    [Abstract] [Full Text] [Related]

  • 6. Comparison of the efficacy and safety of live attenuated cold-adapted influenza vaccine, trivalent, with trivalent inactivated influenza virus vaccine in children and adolescents with asthma.
    Fleming DM, Crovari P, Wahn U, Klemola T, Schlesinger Y, Langussis A, Øymar K, Garcia ML, Krygier A, Costa H, Heininger U, Pregaldien JL, Cheng SM, Skinner J, Razmpour A, Saville M, Gruber WC, Forrest B, CAIV-T Asthma Study Group.
    Pediatr Infect Dis J; 2006 Oct; 25(10):860-9. PubMed ID: 17006278
    [Abstract] [Full Text] [Related]

  • 7. The efficacy of live attenuated, cold-adapted, trivalent, intranasal influenzavirus vaccine in children.
    Belshe RB, Mendelman PM, Treanor J, King J, Gruber WC, Piedra P, Bernstein DI, Hayden FG, Kotloff K, Zangwill K, Iacuzio D, Wolff M.
    N Engl J Med; 1998 May 14; 338(20):1405-12. PubMed ID: 9580647
    [Abstract] [Full Text] [Related]

  • 8. A randomized, double-blind study of the safety, transmissibility and phenotypic and genotypic stability of cold-adapted influenza virus vaccine.
    Vesikari T, Karvonen A, Korhonen T, Edelman K, Vainionpää R, Salmi A, Saville MK, Cho I, Razmpour A, Rappaport R, O'Neill R, Georgiu A, Gruber W, Mendelman PM, Forrest B, CAIV-T Transmission Study Group.
    Pediatr Infect Dis J; 2006 Jul 14; 25(7):590-5. PubMed ID: 16804427
    [Abstract] [Full Text] [Related]

  • 9. Efficacy of live attenuated influenza vaccine in children: A meta-analysis of nine randomized clinical trials.
    Rhorer J, Ambrose CS, Dickinson S, Hamilton H, Oleka NA, Malinoski FJ, Wittes J.
    Vaccine; 2009 Feb 11; 27(7):1101-10. PubMed ID: 19095024
    [Abstract] [Full Text] [Related]

  • 10. Safety and tolerability of cold-adapted influenza vaccine, trivalent, in infants younger than 6 months of age.
    Vesikari T, Karvonen A, Smith HM, Dunning A, Razmpour A, Saville MK, Gruber WC, Forrest BD.
    Pediatrics; 2008 Mar 11; 121(3):e568-73. PubMed ID: 18299305
    [Abstract] [Full Text] [Related]

  • 11. Safety, efficacy and effectiveness of cold-adapted, live, attenuated, trivalent, intranasal influenza vaccine in adults and children.
    Belshe RB, Gruber WC.
    Philos Trans R Soc Lond B Biol Sci; 2001 Dec 29; 356(1416):1947-51. PubMed ID: 11779396
    [Abstract] [Full Text] [Related]

  • 12. Shedding of Ann Arbor strain live attenuated influenza vaccine virus in children 6-59 months of age.
    Mallory RM, Yi T, Ambrose CS.
    Vaccine; 2011 Jun 10; 29(26):4322-7. PubMed ID: 21513761
    [Abstract] [Full Text] [Related]

  • 13. Trivalent live attenuated intranasal influenza vaccine administered during the 2003-2004 influenza type A (H3N2) outbreak provided immediate, direct, and indirect protection in children.
    Piedra PA, Gaglani MJ, Kozinetz CA, Herschler GB, Fewlass C, Harvey D, Zimmerman N, Glezen WP.
    Pediatrics; 2007 Sep 10; 120(3):e553-64. PubMed ID: 17698577
    [Abstract] [Full Text] [Related]

  • 14. Efficacy of inactivated split-virus influenza vaccine against culture-confirmed influenza in healthy adults: a prospective, randomized, placebo-controlled trial.
    Beran J, Vesikari T, Wertzova V, Karvonen A, Honegr K, Lindblad N, Van Belle P, Peeters M, Innis BL, Devaster JM.
    J Infect Dis; 2009 Dec 15; 200(12):1861-9. PubMed ID: 19909082
    [Abstract] [Full Text] [Related]

  • 15. Efficacy of a single dose of live attenuated influenza vaccine in previously unvaccinated children: a post hoc analysis of three studies of children aged 2 to 6 years.
    Block SL, Toback SL, Yi T, Ambrose CS.
    Clin Ther; 2009 Oct 15; 31(10):2140-7. PubMed ID: 19922885
    [Abstract] [Full Text] [Related]

  • 16. Live attenuated versus inactivated influenza vaccine in infants and young children.
    Belshe RB, Edwards KM, Vesikari T, Black SV, Walker RE, Hultquist M, Kemble G, Connor EM, CAIV-T Comparative Efficacy Study Group.
    N Engl J Med; 2007 Feb 15; 356(7):685-96. PubMed ID: 17301299
    [Abstract] [Full Text] [Related]

  • 17. Cost-effectiveness of live-attenuated influenza vaccine, trivalent in preventing influenza in young children attending day-care centres.
    Hibbert CL, Piedra PA, McLaurin KK, Vesikari T, Mauskopf J, Mahadevia PJ.
    Vaccine; 2007 Nov 19; 25(47):8010-20. PubMed ID: 17936446
    [Abstract] [Full Text] [Related]

  • 18. Current status of live attenuated influenza virus vaccine in the US.
    Belshe RB.
    Virus Res; 2004 Jul 19; 103(1-2):177-85. PubMed ID: 15163507
    [Abstract] [Full Text] [Related]

  • 19. Duration of protection provided by live attenuated influenza vaccine in children.
    Ambrose CS, Yi T, Walker RE, Connor EM.
    Pediatr Infect Dis J; 2008 Aug 19; 27(8):744-8. PubMed ID: 18600188
    [Abstract] [Full Text] [Related]

  • 20. Safety of cold-adapted live attenuated influenza vaccine in a large cohort of children and adolescents.
    Bergen R, Black S, Shinefield H, Lewis E, Ray P, Hansen J, Walker R, Hessel C, Cordova J, Mendelman PM.
    Pediatr Infect Dis J; 2004 Feb 19; 23(2):138-44. PubMed ID: 14872180
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 19.